ARS Pharmaceuticals Future Growth
Future criteria checks 5/6
ARS Pharmaceuticals is forecast to grow earnings and revenue by 56.2% and 54.4% per annum respectively while EPS is expected to grow by 56.4% per annum.
Key information
56.2%
Earnings growth rate
56.4%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | 54.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 212 | 40 | N/A | N/A | 2 |
12/31/2025 | 85 | -35 | N/A | N/A | 3 |
12/31/2024 | 6 | -59 | N/A | N/A | 3 |
12/31/2023 | 0 | -54 | -59 | -59 | N/A |
9/30/2023 | 0 | -62 | -63 | -62 | N/A |
6/30/2023 | 0 | -53 | -56 | -55 | N/A |
3/31/2023 | 1 | -42 | -46 | -46 | N/A |
12/31/2022 | 1 | -35 | -40 | -40 | N/A |
9/30/2022 | 2 | -25 | -25 | -25 | N/A |
6/30/2022 | 2 | -25 | -24 | -24 | N/A |
3/31/2022 | 4 | -23 | -21 | -21 | N/A |
12/31/2021 | 6 | -20 | -18 | -18 | N/A |
12/31/2020 | 18 | -1 | 9 | 9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: SPRY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SPRY is expected to become profitable in the next 3 years.
Revenue vs Market: SPRY's revenue (54.4% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: SPRY's revenue (54.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRY's Return on Equity is forecast to be high in 3 years time